ArticleFrontiers in cardiovascular medicine2026
Late gadolinium enhancement CMR for detecting myocardial injury after cancer therapy: a real-world observational study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinically, cardiotoxicity defined by reduced left ventricle ejection fraction (LVEF) in cancer therapy could miss the onset of tissue-level myocardial changes. In this study, we aimed to use late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) to evaluate myocardial injury in patients receiving cancer therapy, and to investigate the effect of LGE and other clinical factors on LV function. Methods: This study included 108 cancer patients and 60 healthy controls examined by CMR imaging. Patients were assigned to the LGE-negative (LGE-, Results: The LVEF and peak strain (PS) in all directions were significantly lower in the patients with LGE than in those without (all Conclusions: The presence of LGE was an important risk factor for LV dysfunction in patients receiving cancer therapy, and the circumferential strain reduction is the predominant mechanism of LV dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.